Works matching IS 17470277 AND DT 2023 AND VI 102 AND IP 1
Results: 19
Lariciresinol protects rats from complete Freund's adjuvant induced arthritis in rats via modulation of transforming growth factor‐β and nuclear factor kappa B pathway: An in vivo and in silico study.
- Published in:
- Chemical Biology & Drug Design, 2023, v. 102, n. 1, p. 168, doi. 10.1111/cbdd.14268
- By:
- Publication type:
- Article
Discovery of [5,5′‐bibenzo[d][1,3]dioxol]‐6‐substituted amine derivatives as potent proprotein convertase subtilisin/kexin type 9 inhibitors.
- Published in:
- Chemical Biology & Drug Design, 2023, v. 102, n. 1, p. 153, doi. 10.1111/cbdd.14264
- By:
- Publication type:
- Article
Explainability and white box in drug discovery.
- Published in:
- Chemical Biology & Drug Design, 2023, v. 102, n. 1, p. 217, doi. 10.1111/cbdd.14262
- By:
- Publication type:
- Article
Saikosaponin A alleviates glycolysis of breast cancer cells through repression of Akt/STAT3 pathway.
- Published in:
- Chemical Biology & Drug Design, 2023, v. 102, n. 1, p. 115, doi. 10.1111/cbdd.14259
- By:
- Publication type:
- Article
Tiratricol, a thyroid hormone metabolite, has potent inhibitory activity against human dihydroorotate dehydrogenase.
- Published in:
- Chemical Biology & Drug Design, 2023, v. 102, n. 1, p. 1, doi. 10.1111/cbdd.14256
- By:
- Publication type:
- Article
A small HDM2 antagonist peptide and a USP7 inhibitor synergistically inhibit the p53‐HDM2‐USP7 circuit.
- Published in:
- Chemical Biology & Drug Design, 2023, v. 102, n. 1, p. 126, doi. 10.1111/cbdd.14255
- By:
- Publication type:
- Article
Local anaesthetic procaine derivatives protect rat against diabetic nephropathy via inhibition of DPP‐4, inflammation and oxidative stress.
- Published in:
- Chemical Biology & Drug Design, 2023, v. 102, n. 1, p. 26, doi. 10.1111/cbdd.14252
- By:
- Publication type:
- Article
A machine learning‐based KNIME workflow to predict VEGFR‐2 inhibitors.
- Published in:
- Chemical Biology & Drug Design, 2023, v. 102, n. 1, p. 38, doi. 10.1111/cbdd.14250
- By:
- Publication type:
- Article
The effects of MYC on exosomes derived from cancer cells in the context of breast cancer.
- Published in:
- Chemical Biology & Drug Design, 2023, v. 102, n. 1, p. 65, doi. 10.1111/cbdd.14245
- By:
- Publication type:
- Article
Retraction Notice.
- Published in:
- 2023
- Publication type:
- Correction Notice
Screening and introduction of key cell cycle microRNAs deregulated in colorectal cancer by integrated bioinformatics analysis.
- Published in:
- Chemical Biology & Drug Design, 2023, v. 102, n. 1, p. 137, doi. 10.1111/cbdd.14242
- By:
- Publication type:
- Article
Glaucocalyxin A attenuates carbon tetrachloride‐induced liver fibrosis and improves the associated gut microbiota imbalance.
- Published in:
- Chemical Biology & Drug Design, 2023, v. 102, n. 1, p. 51, doi. 10.1111/cbdd.14241
- By:
- Publication type:
- Article
TFP5 attenuates cyclin‐dependent kinase 5‐mediated islet β‐cell damage in diabetes.
- Published in:
- Chemical Biology & Drug Design, 2023, v. 102, n. 1, p. 76, doi. 10.1111/cbdd.14235
- By:
- Publication type:
- Article
Molecular targets of metformin against ovarian cancer based on network pharmacology.
- Published in:
- Chemical Biology & Drug Design, 2023, v. 102, n. 1, p. 88, doi. 10.1111/cbdd.14234
- By:
- Publication type:
- Article
Therapeutic efficacy of caffeic acid phenethyl ester in cancer therapy: An updated review.
- Published in:
- Chemical Biology & Drug Design, 2023, v. 102, n. 1, p. 201, doi. 10.1111/cbdd.14233
- By:
- Publication type:
- Article
Current understanding and future prospects on Berberine for anticancer therapy.
- Published in:
- Chemical Biology & Drug Design, 2023, v. 102, n. 1, p. 177, doi. 10.1111/cbdd.14231
- By:
- Publication type:
- Article
Stat5 inhibits NLRP3‐mediated pyroptosis to enhance chemoresistance of breast cancer cells via promoting miR‐182 transcription.
- Published in:
- Chemical Biology & Drug Design, 2023, v. 102, n. 1, p. 14, doi. 10.1111/cbdd.14229
- By:
- Publication type:
- Article
Evodiamine inhibits malignant progression of ovarian cancer cells by regulating lncRNA‐NEAT1/miR‐152‐3p/CDK19 axis.
- Published in:
- Chemical Biology & Drug Design, 2023, v. 102, n. 1, p. 101, doi. 10.1111/cbdd.14228
- By:
- Publication type:
- Article
Cover Image.
- Published in:
- Chemical Biology & Drug Design, 2023, v. 102, n. 1, p. i, doi. 10.1111/cbdd.14080
- Publication type:
- Article